Stock Market Fails To Deliver A ‘Santa Rally’ This Week, Yet… – $ADT $APE $ATXS $CVX $SHIP $XPON Rise!

By John F. Heerdink, Jr.

Quote of the Day: “Be faithful in small things because it is in them that your strength lies.” – Mother Teresa

Happy Saturday All!

I hope that you had a great week and that you are out enjoying the long holiday weekend.

As for the markets this week, we experienced yet another down week for the major indices, except for the Dow 30, which had sports apparel giant Nike (NKE) provide particular strength by moving up 9.72% over the last 5-days post landing the index in the green after reporting an earnings beat and that its inventory issues had been resolved. Once again, a fair amount of tax swap and/or loss selling also added to the overall pressure and hopefully is setting us up for one heck of a January Effect trade and currently no real ‘Santa Rally’ has developed. The January Effect is a hypothesis that there is a seasonal anomaly in the financial market where securities’ prices increase in the month of January more than in any other month. This calendar effect would create an opportunity for investors to buy stocks for lower prices before January and sell them after their value increases. A Santa Claus rally is a calendar effect that involves a rise in stock prices during the last 5 trading days in December and the first 2 trading days in the following January.

The macroeconomic schedule produced another set of reports that unfortunately left many a bit confused if not pessimistic overall. The pessimism in general rang loudly too as few market bears chirped including David Alan Tepper, an American billionaire hedge fund manager, owner of the BNFL’s Carolina Panthers and the MLS’s Charlotte FC, alarming many as he stated that he is short equites pointing towards an environment that he summed up as “difficult for things to go up.” As for as the reports on Monday, the December NAHB Housing Market Index report confirmed another drop to 31. On Tuesday, the total housing starts report confirmed another .5% M/M drop to a seasonally adjusted annual rate of 1.427M units, while single-unit starts dropped by a whopping 4.1% to 828K. We also discover that total building permits fell an even greater 11.2% M/M to a seasonally adjusted annual rate of 1.342M & permits for single-unit dwellings fell 7.1%. On Wednesday, the consumer confidence data report came in higher than expected at 108.3 and the Existing Home sales report that confirmed a whopping 7.7% M/M drop in November. The weekly MBA Mortgage Applications Index report confirmed a .9% rise. Refinancing applications also surged 6%, however purchase applications sagged by .1%. The Existing home sales report cascaded a 7.7% M/M in November to a seasonally adjusted annual rate of 4.09M, leaving Total sales in November off a whopping 35.4% compared to a year ago. The Current Account Balance report showed a drop to -$217.1B in Q3. Total sales in November were down 35.4% from a year ago. The Weekly EIA Crude Oil Inventories report confirmed a 5.894M barrel draw. On Thursday, the third estimate for Q3 GDP report confirmed a rise in consumer spending by 2.3% and assisted in creating an upward revision for Q3 GDP growth to 3.2%. The GDP Price Deflator report also confirmed a move up to 4.4%. The Initial claims report for the week ending December 17 confirmed a move to 216k up 2k, however, continuing claims for the week ending December 10 dropped by 6k to 1.672M. The Leading Economic Index report showed a 1% drop in November. The Weekly EIA Natural Gas Inventories report came in with a 87 bcf draw.On Friday, the Personal income report confirmed a .4% M/M rise in November, while personal spending rose .1%. The PCE Price Index rose .1%M/M, while on a Y/Y basis. The Durable goods orders report in November came in lower by 2.1% M/M. The New home sales report came in 5.8% higher M/M in November to a seasonally adjusted annual rate of 64ok units, leaving new home sales lower by 15.3% Y/Y. The final December University of Michigan Index of Consumer Sentiment came in higher at 59.7.

Interestingly, the yield curve pulled back with the 2-yr note yield increased by 11 basis points to close at 4.31% & the 10-yr note yield moving up by 26 basis points to close at at 3.75%.

Oil prices closed on Friday to end at $79.55/bbl and up 5.53% over the last 5-days.

The US dollar stayed within a tight range again and closed at $104.33, which is just down from the $104.84 level it closed last Friday.

At the end of the week, the major indices closed with he S&P 500 closed at 3,844.82 (-.2%) for the week and is now down 19.3% YTD. 6 of the 11 sectors closed in the green with the energy sector rising 4.4% to lead all. The consumer discretionary sector off another 3.1% (+6% over the last 2-wks) and the information tech sector off 2% took the hardest hits once again this week. The 6.82% weighting of Apple (AAPL) placed some significant pressure once again again this week closing at $131.86, moving down 1.97% over the last 5-days. The Dow 30 closed higher at 33,203.90 (+.9%) and is down -8.6% YTD. The Nasdaq legged down again and closed at 10,497.80 (-1.9%) for the week and is down 32.9% YTD. The CBOE Volatility Index (^VIX) closed at $20.87, off a solid 7.74% over the last 5-days and remains up +21.20% YTD. The small caps on the Russell 2000 ticked lower and closed at 1,760.93 (-.1%) & is now down 21.6% YTD. The MicroCaps showed relative strength this week as the iShares Micro-Cap ETF (IWC) closed at $106.23, down .23% over the last 5-days and is now down 23.90% YTD.

BIOTECH AND HEALTHCARE

Biotech stocks fell overall this week, but recently the sector has seen an increase of significant mergers, acquisitions, and public offerings, traditionally good signs that the situation getting ‘cleaned up’ in this recently beaten down sector. This week, Astria Therapeutics, Inc. (Nasdaq: ATXS, $14.80, +25.32% over the last 5-days), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, announced the closing of its previously announced underwritten offering of 10,445,050 shares of its common stock, including the full exercise of the underwriters’ option to purchase 1,362,397 shares of common stock, at a price of $11.01 per share. The gross proceeds of the offering were approximately $115 million, before deducting underwriting discounts and commissions and other offering expenses. Also, Prothena Corporation plc (NASDAQ:PRTA, $57.82, +1.72% over last 5-days), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the public of $56.50 per ordinary share, before the underwriting discount and estimated offering expenses. All of the ordinary shares in the offering were sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 487,500 of its ordinary shares. Net proceeds to Prothena from the ordinary shares to be sold by Prothena in the offering are expected to be $172.4 million, after deducting the underwriting discount and estimated offering expenses, but excluding any exercise of the underwriters’ option to purchase additional ordinary shares.

The Nasdaq Biotechnology ETF (IBB) moved down and closed at $132.03, -.73% over the last 5-days & is down 13.49% YTD. The NYSE ARCA Biotech Index (^BTK) closed at 5,296.05, -.57% over the last 5-days and is now down 4.03% YTD. The SPDR S&P Biotech ETF (XBI) closed at $80.88, -.10% over the last 5-days & is now down 27.76% YTD. The 52-week range is is now $61.78-$119.21.

The iShares U.S. Healthcare ETF (IYH) closed at $283.90, +.71% over the last 5-days and is down -5.48% YTD.

Johnson & Johnson Inc. (JNJ, $177.48, up 1.03% over the last 5-days) closed its acquisition of medical device maker heart pump maker Abiomed Inc. on Thursday for $16.6B.

EV, TECH, CONSUMER, FINANCIALS

Apple (AAPL) closed at $131.86, -1.97% over the last 5-days, nearly 12% over the last two weeks. Apple represents a 6.82% weighting in the S&P 500. On Dec. 22, Apple Inc’s workers in Australia initiated a strike Friday afternoon, demanding better working conditions and wages, a workers’ union said, a move that might dent sales of the tech giant during the peak Christmas shopping time.

tesla

EV giant Tesla (TSLA) closed at $123.15, -18.03% over the last 5-days.

On Dec. 22, Tesla started offering U.S. car buyers $7.5k to take delivery of new Model 3 sedans & Model Y sport utility vehicles prior year-end, doubling what had already offered earlier in December.

On Tuesday, EvercoreISI analyst Chris McNally cut his price target to $200 from $300.

On Dec. 19, adding yet another twist to the Tesla/Elon volatile story, Elon Musk tweeted, “Should I step down as head of Twitter? I will abide by the results of this poll.” He released the results where 57% voted Yes! Note that on Musk also sold 22 million shares for $3.6 billion on Dec. 14. Cathie Wood along with a group of funds of Ark Investment Management bought more shares of Tesla recently as it has continued to dip.

Shares of JPMorgan (JPM) closed at $131.28, +.47% over the last 5-days. JPMorgan will host a conference call to review fourth-quarter and full-year 2022 financial results on Friday, January 13, 2023 at 8:30 a.m. (EST). The results are scheduled to be released at approximately 7:00 a.m. (EST). The live audio webcast and presentation slides will be available on www.jpmorganchase.com under Investor Relations, Events & Presentations.

On December 13, the Board of Directors of JPMorgan declared a quarterly dividend of $1.00 per share on the outstanding shares of the common stock of JPMorgan Chase. The dividend is payable on January 31, 2023, to stockholders of record at the close of business on January 6, 2023.

Shares of Amazon.com, Inc. (AMZN) closed $85.25, -2.97% over the last 5-days. On December 15, Amazon Games and Crystal Dynamics announced they have reached an agreement under which Crystal Dynamics will develop a new multi-platform Tomb Raider title, with Amazon Games providing full support and publishing the game globally. The as-yet-untitled new Tomb Raider game is a single-player, narrative-driven adventure that continues Lara Croft’s story in the Tomb Raider series. It includes all the elements that have made Tomb Raider one of the most revered franchises in gaming, giving players control of the confident and multidimensional hero Lara Croft in an environment that rewards exploration and creative pathfinding, with mind-bending puzzles to solve, and a wide variety of enemies to face and overcome. Crystal Dynamics is drawing on the power and cutting-edge technology of Unreal Engine 5 to take storytelling to the next level, in the biggest, most expansive Tomb Raider game to date. The title is currently in early development, and additional details will be announced at a later date.

Shares of Microsoft Corp. (MSFT) closed at $238.73, -2.44% over the last 5-days. On Dec. 14, Microsoft Corp. and Viasat (NASDAQ: VSAT) announced a new partnership to help deliver internet access to 10 million people around the globe, including 5 million across Africa. Viasat, a global communications company, is the first satellite partner to work with Microsoft’s Airband Initiative, and together they will deepen Airband’s work in the Democratic Republic of the Congo, Nigeria, Guatemala, Mexico, and the United States, as well as prioritize expanding the program to Egypt, Senegal and Angola to deliver much-needed internet connection, often for the first time. This first of its kind global partnership for Airband is an important step in reaching the Initiative’s expanded goal of delivering internet access to a quarter of a billion people across the world, including 100 million people on the continent of Africa, by the end of 2025.

Shares of Salesforce, Inc. (CRM) closed at $129.44, +.91% over the last five days. On Dec. 8, Salesforce announced that Genie Customer Data Cloud, the #1 CRM data cloud, is now powered by Tableau, helping businesses better understand and unlock customer data and deliver actionable insights in real time and at scale. Now, any company can analyze billions of data points stored and harmonized in Genie using Tableau, and then visualize, explore, and automate insights and take action securely. In addition, because Genie is natively integrated with Tableau, businesses can drive down data warehousing costs, increase time to insight, and enable better decision making by bringing all their data and analytics together in one place. Genie Customer Data Cloud now processes more than 100 billion customer records on average daily across the entire Salesforce Customer 360, enabling every company to use data and become a customer company by saving time and money while growing revenue.

Shares of NVIDIA (NVDA), a pioneer in accelerated computing, closed at $152.06, -8.24% over the last 5-days. On Dec. 7, KULR Technology Group, Inc. ( KULR), a leading energy management platform company accelerating the global transition to a sustainable electrification economy, announced that it will be expanding its vibration reduction solution KULR VIBE offering with the launch of a scalable, centralized artificial intelligence (“AI”) server platform. Powered by NVIDIA accelerators, the updated KULR VIBE system will deliver faster processing speeds and data capture for remote access.

Cathie Wood’s ARK Innovation ETF (ARKK) closed at $30.97, -6.89% over the last 5-days. Cathie Wood along with a group of funds of Ark Investment Management bought more shares of Tesla as it has continued to dip.

The Technology Select Sector SPDR Fund (XLK) closed at $124.60, -2.26% over the last 5-days.

Shares of McDonald’s (MCD) closed at $267.57, +.54% over the last 5-days. On December 15, McDonald’s Corporation and all five members of the restaurant chain’s North American Logistics Council (NALC) – Armada, Earp Distribution, Martin Brower, Mile Hi Foods and The Anderson-DuBose Company – have signed agreements with Enel North America to purchase renewable energy and the associated renewable energy certificates (RECs) from Enel Green Power’s Blue Jay solar project in Grimes County, Texas. This innovative aggregation of a major company purchasing power jointly with its logistics partners means the electricity load of McDonald’s USA’s entire logistics supply chain for all its U.S. restaurants is expected to be 100% supported by renewable energy. The Blue Jay solar project is expected to be fully operational in 2023. Once complete, McDonald’s and its suppliers’ combined electricity purchase is expected to amount to an estimated average of over 470,000 megawatt hours (MWh) of renewable energy annually. This is equivalent to avoiding over 170,000 metric tons of carbon emissions annually or the greenhouse gas (GHG) emissions from over 80 million trucking miles driven each year.

GOLD & SILVER

Gold prices closed at $1803/oz., +$3/oz. & silver prices closed at $23.85/oz., +$.50/oz. for the week.

Hecla Mining (HL) closed at $5.50, +3.77% over the last 5-days & First Majestic (AG) closed at $8.68, +1.28% over the last 5-days.

MEMES CENTRAL

AMC Entertainment (AMC) closed at $4.40, -17.14% & (APE) closed at $1.73, +136.99% over the last 5-days. On Dec. 22, AMC Entertainment Holdings announced it will raise $110 million of new equity capital through the sale of APE units to Antara Capital, LP (“Antara”) in two tranches at a weighted average price of $0.660 per share. The APE unit closing price on the New York Stock Exchange on December 21, 2022 was $0.685. Under the terms of the agreement, Antara, a current AMC debt holder, will also exchange $100 million principal amount of 2nd Lien Notes due 2026 for approximately 91.0 million APE units thereby reducing AMC’s outstanding debt by $100 million. As a result of the $100 million principal debt reduction, future annual interest expense will be reduced by approximately $10 million. Learn More.

GameStop (GME) closed at $20.08, -3.46% over the last 5-days as the shorts won again overall this week. Note that approx. 20% of GME’s outstanding shares are sold short landing it with a short interest ratio of 7.6. On Dec. 7, GME released financial results for the third quarter ended October 29, 2022 highlighting that Net sales were $1.186 billion, compared to $1.297 billion in the prior year’s third quarter & that Sales attributable to new and expanded brand relationships were strong in the quarter, while sales in the collectibles category remained strong on a year-to-date basis.

Seanergy Maritime Holdings Corp. (SHIP) closed at $.574, +12.55% over the last 5-days. On Dec. 9, Seanergy announced the filing of an amendment to its Schedule To and Offer to Purchase (the “Amendment”), both dated as of November 30, 2022, relating to the Company’s tender offer to purchase all outstanding Class E common stock purchase warrants (the “Warrants”) at a purchase price of $0.20 per Warrant, which tender offer will expire at the end of day, 5:00 P.M., Eastern Time, on January 10, 2023, unless extended or withdrawn. The Company has filed the Amendment on Schedule TO and the Amendment may be accessed from the Securities and Exchange Commission’s website at www.sec.gov.

On Nov. 30 after the close, SHIP announced its financial results for the third quarter and nine months ended September 30, 2022. The Company also declared a quarterly dividend of $0.025 per share for the third quarter of 2022.

CRYPTO & BITCOIN

Bitcoin (BTC) closed at $16,826.58, +2.35% over the last 5-days at the time this report was prepared.

ENERGY

The Energy Select Sector SPDR Fund or ETF (XLE) closed at $87.06, +3.20% over the last 5-days. Chevron (CVX) closed at $177.40, +3.09% over the last 5-days. On Dec. 14, Chevron Corporation, through its Chevron New Energies business, and Baseload Capital have announced a joint venture to develop geothermal projects in the United States. The two companies will collaborate on driving geothermal opportunities – including identifying the best prospects for development, operations and progressing the next generation of geothermal technologies from pilot to commercial scale. Through this agreement, Chevron and Baseload Capital will work together to create awareness around geothermal energy which will be a critical supply option for renewable energy. Warren Buffet’s pick in the sector, Occidental Petroleum (OXY) closed at $63.95, +2.27% over the last 5-days.

Oil prices closed on Friday to end at $79.55/bbl and up 5.53% over the last 5-days.

NEXT WEEK

Note the markets will be closed on Monday, December 26 to observe the Christmas holiday this year.

VP WATCHLIST UPDATES

Please review a select group of emerging names below and their updates below:

Shares of ADT Inc. (ADT), the most trusted brand in smart home and small business security, closed at $9.16, +.33% over the last 5-days, but established a new 52-wk high at $10.10 along the way.

On Dec. 16, ADT announced that Jamie Haenggi has been appointed to lead ADT Solar, a division of ADT Inc. Haenggi served as executive vice president and chief operating officer of ADT Solar since March and will now lead all functions within the division. Marc Jones, founder of Sunpro, which was acquired by ADT in 2021 and rebranded as ADT Solar, will serve as senior advisor to Haenggi. Jones previously served as executive vice president, ADT Solar. Haenggi joined ADT in 2016 and has served the company in executive roles within sales, marketing and customer experience. She also serves on the board of directors of Enphase Energy.

On Nov. 3, ADT, announced its results for the third quarter of 2022. They highlighted Total revenue of $1.6 billion, up 22% or 8% excluding Solar, and end-of-period Recurring Monthly Revenue (RMR) of $372 million, up 4%, Record high customer retention with gross customer revenue attrition at 12.6%, Record revenue payback of 2.1 years, & GAAP net loss of $122 million, or a loss of $(0.13) per diluted share, down $13 million. The board of ADT announced that it will pay a dividend of $.035.share on the 4th of January or 1.6% yield.

On Oct. 13, ADT, announced that it has issued and sold in a private placement to State Farm 133.3 million shares of ADT common stock for a gross purchase price of $1.2 billion. In September, ADT announced a new partnership with State Farm to revolutionize the homeownership experience through innovation in the detection and mitigation of property losses. In addition to the equity investment, State Farm has committed up to $300 million to fund product and technology innovation, customer growth and marketing activities in connection with the partnership. State Farm has funded the first $100 million and the two companies will collaborate to approve initiatives utilizing the funds.

Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $11.01.

- On Nov. 7, Fate Therapeutics announced that ONO Pharmaceutical Co., Ltd. (ONO) has exercised its option to FT825/ONO-8250, a multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) T-cell product candidate targeting human epidermal growth factor receptor 2 (HER2)-expressing solid tumors. The preclinical product candidate incorporates multiple functional elements to enhance the activity and overcome unique challenges in treating solid tumors with cell-based cancer immunotherapies. “We are encouraged by the compelling preclinical data package generated for FT825/ONO-8250 under our collaboration, which combines the antigen binder that ONO provides and Fate’s industry-leading iPSC product platform to overcome the challenges in solid cancer treatment,” said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of ONO. “We look forward to initiating clinical development of the off-the-shelf, iPSC-derived CAR T-cell product candidate with the aim of delivering benefit to patients with some of the most difficult to treat cancers.”

- November 3, Fate reported business highlights and financial results for the third quarter ended September 30, 2022 with Cash, cash equivalents and investments as of September 30, 2022 were $519.1 million. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “We are very pleased with the positive feedback from the FDA under our FT516 RMAT designation in support of our iPSC product platform and potential registrational pathways for the treatment of relapsed / refractory aggressive lymphomas, including for patients who have previously failed CD19-targeted CAR T-cell therapy, and we look forward to engaging the FDA in the fourth quarter to discuss CMC topics in support of pivotal trial readiness. We are also excited to present interim Phase 1 clinical data at the upcoming SITC and ASH conferences, including for our iPSC-derived CAR NK cell programs FT576 in multiple myeloma and FT536 in solid tumors as well as for the first-ever iPSC-derived CAR T-cell program FT819 in B-cell lymphoma. Finally, under our collaboration with Janssen, we are pleased to announce our first IND candidate FT555, a multiplexed-engineered, iPSC-derived CAR NK cell targeting GPRC5D for multiple myeloma, and that Janssen has also exercised its commercial option to an additional product candidate targeting an undisclosed hematologic malignancy antigen.”

- Fate announced that fourteen presentations for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held in New Orleans, Louisiana, or virtually, December 10-13, 2022.

Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and radiation-induced lung injury, closed at $.5758.

- On Dec. 7, Atossa announced the appointment of Eric Van Zanten as Vice President of Investor and Public Relations. Mr. Van Zanten brings over 25 years of corporate communications experience working within the biopharmaceutical, finance, and healthcare industries. He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company. Prior to joining Atossa, Mr. Van Zanten led corporate affairs at Faron Pharmaceuticals, a clinical stage biopharmaceutical company focused on tackling difficult-to-treat cancers via precision macrophage immunotherapy and Urogen Pharma, a commercial stage biotech delivering innovative solutions that treat specialty cancers. He was also formerly Head of Commercial and Medical Communications and Director of Oncology Communications at Bristol-Myers Squibb where he helped launch Opdivo, one of the most successful oncology brands ever. Earlier in his career he held communications leadership roles at Deloitte, Booz Allen & Hamilton, Children’s Hospital of Philadelphia and Unisys Corporation.“We are excited to welcome Eric to Atossa as we sharpen our focus on developing new therapies for cancer patients,” said Steven Quay, M.D., Ph.D., President and Chief Executive Officer of Atossa. “His extensive industry experience and oncology background make him particularly well-suited to help us share the Atossa story with investors, researchers, media, industry partners and other stakeholders.”

- On Nov. 7, Atossa announced its financial results for the fiscal quarter ended September 30, 2022, and provided an update on recent company developments. Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. Key developments from Q3 2022 and to date included:
  - Received FDA authorization from FDA to initiate its Phase 2 study of neoadjuvant (Z)-endoxifen in premenopausal women with ER+/HER2- breast cancer.
  - Invested in a privately-held Dynamic Cell Therapies, a company focused on CAR-T therapies as an important step in pursuing its strategy to develop CAR-T therapies or adjacent opportunities within the immuno-oncology space.
  - Completed dosing in both Part B and Part C (of four parts) of Phase 1/2a Clinical Trial of AT-H201 in healthy volunteers, which the Company is now developing for patients with compromised lung function due to the damaging effects of cancer treatment.

- On November 1, Atossa announced that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc. (DCT), a venture capital backed company that is based in Boston, MA. DCT is in the pre-clinical phase of developing controllable CAR-T cells to address difficult-to-treat cancers. Its platform technology of dynamic control of engineered T-cells is designed to improve the safety, efficacy, and durability of CAR-T cell therapies. This system should find initial applications in hematological cancers, with future approaches in solid tumors and autoimmune diseases. The company’s platform technology uncouples tumor targeting from CAR-T cell activation. Each CAR-T cell recognizes an inert small molecule. This small molecule is conjugated to a tumor-specific antibody. By dosing a small molecule-antibody conjugate, the physician could dynamically control CAR-T cell activity and potentially minimize the risk of life-threatening side effects. Increasing the dose of the small molecule-antibody conjugate should strengthen the immune attack against tumor cells. In addition, the same small molecule can be coupled to different tumor targeting antibodies, allowing the physician to maximize on-target on-tumor efficacy and reduce off-tumor toxicities. To learn more, please visit www.dynamiccelltherapies.com. Steven Quay, M.D., Ph.D., Atossa’s CEO, Chairman and President stated, “This investment in DCT is an important step in pursuing our strategy to develop CAR-T therapies or adjacent opportunities within the immuno-oncology space. We believe that as an active investor in the development of DCT we will be well positioned to evaluate future opportunities while strategically managing our cash position.” Atossa will acquire shares equal to 19.99% of the outstanding capital stock of DCT as of today for a cash payment of $2 million (in addition to $3 million previously paid to DCT). The transaction is expected to close in the fourth quarter.
- On October 25, Atossa announced that it has retained Richard Graydon, M.D., Ph.D. as interim chief medical officer. Dr. Graydon will devote all of his professional time to the Atossa clinical programs. Prior to joining Atossa, Dr. Graydon served as Senior Director of Clinical Development at Johnson and Johnson (JNJ) where he was responsible for leading compound development and clinical trial programs for Janssen Pharmaceuticals. At Janssen, he oversaw the early to late-stage development and the 2022 approval of BCMA-directed CAR T-Cell therapy (cilta-cel) for Multiple Myeloma, as well as daratumumab, imbruvica, siltuximab and other compounds for solid tumor and hematological malignancies. Previously, he held the role of Director of Clinical Development at Daiichi Sankyo, Inc., where he led the early and late-stage development of the small molecule targeted therapy quizartinib for FLT3-positive Acute Myeloid Leukemia. Additionally, he led the early-stage development of the MDM2 inhibitor milademetan in hematological malignancies and liposarcomas. Dr. Graydon spent time in clinical practice following completion of his specialty training in hematology and oncology at Harvard Massachusetts General Hospital. He earned his M.D. and Ph.D. at Stanford University, and undergraduate degree in Chemical Engineering at Cornell University. Dr. Graydon is the author of The Genetic Risks of Cancer: The Effects of DNA, Genomics and Inheritance on Aging and Survival.
- On Oct. 24, Atossa announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and authorized initiation of its Phase 2 neoadjuvant clinical study of (Z)-endoxifen in premenopausal women with early-stage estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer. This is the first study of Atossa’s proprietary (Z)-endoxifen in the United States. At this time, Atossa also announced that it is discontinuing its COVID-19 program (AT-301) so that it can refocus resources on this critical study in breast cancer. “Continuing the development of our proprietary (Z)-endoxifen here in the United States has been a key goal which builds on the recent issuance of a U.S. patent for our proprietary (Z)-endoxifen and results from our Phase 2 “window-of-opportunity” study in Australia,” commented Steven Quay, M.D., Ph.D., Atossa’s CEO, Chairman and President. “We are excited to have engaged Dr. Matthew Goetz, the Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D. at Mayo Clinic and Director of the Mayo Clinic Breast Cancer SPORE, as the lead principal investigator for this multi-center study. We look forward to opening the study in the fourth quarter.”

The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many patients (upwards of 90% by many estimates) unable to access affordable treatment. INVO Bioscience, Inc. (NASDAQ: INVO) offers the INVOcell solution which provides an advanced, effective and affordable infertility treatment to help increase access to care. INVO is commercially advancing INVOcell through the opening of INVO Centers, opportunistically now pursuing acquisitions of established fertility (IVF) clinics in the U.S., and continuing to offer the technology to existing fertility practices. Shares INVO closed at $.41 and then moved up +18.90% to $.4875 in the aftermarket on Friday. The 52-wk range is $.3290 – $4.059.

READ our recently published story that is gaining traction titled “INVO Bioscience (NASDAQ: $INVO), A Company Seeking To Address A Massively Underserved Fertility Market.”

- On Nov. 30, INVO announced the birth of the first baby in Malaysia utilizing the INVOcell solution. The healthy baby boy weighed 3.53 kg and was born on November 11, 2022 at Tuanku Mizan Military Hospital in Kuala Lumpur. Physicians at Advanced Reproductive Centre (ARC), at Hospital Canselor Tuanku Muhriz (HCTM), at the National University of Malaysia conducted the IVC procedure. The patient was part of a prospective peer reviewed study of INVOcell compared to conventional IVF (“cIVF”) that took place at ARC at HCTM. The study, titled “Comparison of Treatment Outcomes among Sibling Oocytes Using Different Culture Systems—Conventional IVF versus INVOcell Device—And Evaluation of INVOcell User Satisfaction: The INVOcIVF Study,” was published in the International Journal of Environmental Research and Public Health. “We couldn’t be more pleased to have been a part of this family’s journey towards parenthood,” commented Steve Shum, CEO of INVO Bioscience. “The INVOcell solution is playing a key role in providing families across the world an alternative method to parenthood by leveraging its innovative medical device to allow fertilization and early embryo development to take place in vivo within the woman’s body; an approach that provides for affordable, high-quality, patient-centered fertility care.” Key findings of the study included:
  - The fertilization rate and good embryo quality were comparable (not significantly different) between INVOcell and cIVF.
  - Although both methods produce similar fertilization rates and good-quality embryos, the blastulation rates were better in the INVOcell group.
  - INVOcell can be used as an alternative method for reproductive treatment in carefully selected patients without jeopardizing outcomes.
  - cIVF is costly and not applicable in most rural and district areas, therefore, the INVOcell can be utilized as a cost-effective alternative to cIVF without sacrificing comfort and outcomes.

- On Monday, November 14, INVO announced financial results for the third quarter ended September 30, 2022 and provided a business update. Revenue (excluding license revenue) was $235,321 compared to $40,303 in the third quarter of the prior year, an increase of 484% and up 61% sequentially compared to the second quarter of 2022. Clinic revenue increased to $176,395, or 370%, compared to the same period last year, and was up 57% sequentially compared to Q2 2022. All reported clinic revenue is derived from the Company’s Atlanta, Georgia-based INVO Center which is consolidated in the financial statements. Revenue from clinics, inclusive of both those accounted for as consolidated and under the equity method, was $450,131, an increase of 1,100% compared to last year and up 111% sequentially compared to the second quarter of 2022. Product sales increased to $58,926 during Q3 2022, an increase of 2,012% compared to the same quarter last year and were up 74% sequentially compared to the second quarter of 2022. INVO has completed due diligence on the previously announced fertility clinic acquisition target and is working to finalize definitive agreements..

- ***INSIDER BUYING ALERT***– On Friday June 3, after the close, a number of Form 4’s were filed c. at www.sec.gov confirming that the CEO, COO, CFO and 5 members of the board of directors purchased shares at $.95/share on June 1, 2022. Here’s the link to view all of the share purchases.

Shares of Chinook Therapeutics, Inc. (KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, closed at $26.49, +4.21% over the last 5-days after establishing a new 52-wk high of $27.44 this week.

- On Nov. 10, Chinook provided a business update and reported financial results for the quarter and nine months ended September 30, 2022. “During the third quarter of 2022, we continued advancing our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases. We are pleased with the strong data presented at ASN Kidney Weekend 2022 from both our lead programs, atrasentan and BION-1301, in IgA nephropathy (IgAN), as well as from CHK-336 and our preclinical research approach,” said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. “We look forward to 2023, when we plan to initiate a phase 3 study of BION-1301 in patients with IgAN, present data from the ongoing phase 1 clinical trial of CHK-336 in healthy volunteers in the first half and report topline proteinuria data from the ongoing phase 3 ALIGN study of atrasentan in the third quarter.”

Borqs Technologies, Inc. (Nasdaq: BRQS, $.21), a global provider of 5G wireless solutions, Internet of Things (IoT) solutions, and innovative clean energy, recently provided the following updates on the Company.

On Dec. 19, Borqs announced the Company has received a letter dated December 13, 2022 (the “Letter”) from the Department of the Treasury on behalf of the Committee on Foreign Investment in the United States (“CFIUS”) stating that the Company is required to negotiate with CFIUS to fully divest its ownership interests and rights in Holu Hou Energy LLC (“HHE”) due to HHE solar energy storage system and EnergyShare technology for Multi-Dwelling Residential Units (“MDU’s”) being deemed a critical technology and therefore a potential national security risk. As stated in the Letter, HHE is considered a top ten solar energy storage supplier in Hawaii, has only been increasing its dominant market share, expects to grow at an exponential rate, and focuses on multi-family dwelling units which are common in military housing. Due to Borqs’ IoT software development and hardware sourcing capabilities in China, CFIUS is concerned that through Borqs, the PRC could gain significant visibility and exert influence over HHE’s business operations and get access to HHE critical technology. CFIUS is requiring the Company to design a plan to mitigate all identified national security risks to the satisfaction of CFIUS. Borqs intends to comply to the requirements from CFIUS and enter into a National Security Agreement with various departments of the U.S. Government with a plan that is effective, monitorable and verifiable to voluntarily divest Borqs’ investment interests and rights in HHE (the “Plan”). HHE’s commercialization of its solar energy storage system and novel EnergyShare technology for MDU’s has enabled the company to open up a new market segment for renewable energy in the USA – likely worth several billions of dollars. In the last year the Company’s MDU development pipeline has reached thousands of individual units in Hawaii alone, with California MDU potential being at least one to two orders of magnitude higher in the coming years. One segment of this new market is for communities of military and other government personnel. The overall MDU opportunity is significant for the company and significant for the USA. Since Borqs’ financial support in HHE starting from October 2021, HHE has signed approximately $50 million in contracts and has a growing pipeline approaching half a billion dollars. We believe this voluntary mitigation will enable the tremendous inherent value of HHE to be realized and that the divestment can be a profitable transaction for Borqs’ shareholders. The Plan to mitigate will include engaging a nationally recognized investment bank with experience in administering competitive sales and auction processes, assigning and hiring of security and monitoring personnel to directly communicate with CFIUS, immediate and complete removal of all Borqs administrative and technical influence over HHE, immediate voluntary reduction of Borqs ownership of HHE from a majority to a minority position and with the target of divesting all. The Company believes such points will enable the Company to accomplish the divestment in an orderly manner.
On Dec.8, Borqs announced its subsidiary, Holu Hou Energy (HHE), has received multiple purchase orders for its HoluPower xP solar energy storage systems for installation at homeowner locations in the Greater San Diego area in California. These orders represent the first for the Company in California. Whereas in Hawaii HHE works to develop and construct Single-Family Residential projects as an “end to end” provider, the Company will target the California homeowner market through already existing channel partners that will sell and construct the projects. For Multi-Dwelling Unit (MDU) Residential properties in the State, the Company will initially target apartment owners, REITs and other MDU stakeholders directly, then partner with existing licensed contractors for system construction. HHE has been focused on the Hawaii market since it began commercial shipments in 2020, in order to become successfully established in the largest market in the United States based upon solar installation penetration. Now it is turning to California, the largest market in terms of size of available opportunity. HHE recently completed the testing and documentation required for the HoluPower xP to be listed as an approved product by the California Energy Commission. The Company expects to be listed by early January 2023, after which permitting and installations can commence. In Hawaii, Holu Hou Energy has quickly become a leader for solar energy storage systems in the Single-Family Residential market, and has essentially created the previously untapped Multi-Dwelling Unit (“MDU”) Residential market for renewable energy by virtue of its “EnergyShare” technology. The same leading product attributes will benefit MDU property owners and homeowners in California. The potential available MDU market in California is believed to be in the billions of dollars. EnergyShare enables networked systems to share excess generation behind their respective utility meters, a game-changer for improving the project economics for the MDU market, including for low-income housing, rental property units and Home Owners Association managed condominiums and town homes. EnergyShare enables more energy to be delivered to load, and fewer batteries to be installed than the standard approach of a unit-by-unit installation.
On Dec. 8, Borqs announced its subsidiary, Holu Hou Energy (HHE), has received multiple purchase orders for its HoluPower xP solar energy storage systems for installation at homeowner locations in the Greater San Diego area in California. These orders represent the first for the Company in California. Whereas in Hawaii HHE works to develop and construct Single-Family Residential projects as an “end to end” provider, the Company will target the California homeowner market through already existing channel partners that will sell and construct the projects. For Multi-Dwelling Unit (MDU) Residential properties in the State, the Company will initially target apartment owners, REITs and other MDU stakeholders directly, then partner with existing licensed contractors for system construction. HHE has been focused on the Hawaii market since it began commercial shipments in 2020, in order to become successfully established in the largest market in the United States based upon solar installation penetration. Now it is turning to California, the largest market in terms of size of available opportunity. HHE recently completed the testing and documentation required for the HoluPower xP to be listed as an approved product by the California Energy Commission. The Company expects to be listed by early January 2023, after which permitting and installations can commence. In Hawaii, Holu Hou Energy has quickly become a leader for solar energy storage systems in the Single-Family Residential market, and has essentially created the previously untapped Multi-Dwelling Unit (“MDU”) Residential market for renewable energy by virtue of its “EnergyShare” technology. The same leading product attributes will benefit MDU property owners and homeowners in California. The potential available MDU market in California is believed to be in the billions of dollars. EnergyShare enables networked systems to share excess generation behind their respective utility meters, a game-changer for improving the project economics for the MDU market, including for low-income housing, rental property units and Home Owners Association managed condominiums and town homes. EnergyShare enables more energy to be delivered to load, and fewer batteries to be installed than the standard approach of a unit-by-unit installation.

- To view a video clip of a recently completed HHE Multi-Unit Residential project go to: https://www.youtube.com/watch?v=kakbynGM-fQ

Shares of InMed Pharmaceuticals Inc. (INM), a leader in the research, development and manufacturing of rare cannabinoids, closed at $1.32 and the traded up to $1.65, +25% in the aftermarket.

On Dec. 16, InMed confirmed that, at its annual general meeting of shareholders held on December 15, 2022 (the “Meeting”), all of the matters put forward before shareholders for consideration and approval as set out in InMed’s notice of meeting and management information circular, dated October 28, 2022, were approved by the shareholders. In particular, shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. See results.
On Dec. 12, InMed announced the Company has entered into a service contract with Brio Financial Group to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022. Brio is a financial and management consulting group based in Bridgewater, New Jersey. The firm provides outsourced financial management and financial reporting support to small and middle market entities. Currently, the team provides consulting services to over 50 private and publicly traded companies. Additionally, the Company announces that its auditor, KPMG, has resigned effective as of December 8, 2022, and that the Audit Committee of the Board of Directors of the Company approved the engagement of Marcum LLP as its auditor, subject to Marcum’s completion of their client acceptance procedures. Marcum will stand for appointment at the Company’s Annual General Meeting, currently scheduled for Thursday, December 15, 2022. KPMG has confirmed that there are no reportable events (as such term is defined in National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”)).

On Nov. 21, InMed announced the closing of its previously announced private placement with two healthcare-focused institutional investors for the issuance and sale of 1,818,185 of its common shares at a purchase price of $3.30 per share (or pre-funded warrant in lieu thereof) priced at-the-market under Nasdaq rules. In addition, the Company has issued to the investors in the offering unregistered preferred investment options (the “investment options”) to purchase up to an aggregate of 3,272,733 common shares. The aggregate gross proceeds to the Company from the private placement were approximately $6 million. The Company intends to use the net proceeds from the offering to continue pipeline development of its pharmaceutical drug candidates, advance manufacturing know-how of cannabinoids and cannabinoid analogs, support intellectual property development and other commercial activities, and for general working capital purposes.

On Nov. 17, Tribe Public’s Webinar Presentation and Q&A Event was co-hosted by Eric A. Adams, CEO & Eric C. Hsu, PhD, Senior Vice President, Pre-Clinical Research & Development of InMed Pharmaceuticals (NASDAQ: INM. They delivered a presentation titled “Exploring The Neuroprotective Qualities of Rare Cannabinoids”& addressed a Q&A session at the end of the presentation. You may now watch the event video art the Tribe Public YouTube Channel at this link.

Shares of Expion360, Inc. (NASDAQ:XPON), an industry leader in lithium ion battery power storage solutions, rose to $2.35, up +139.82% trading 48.77M shares on Friday. On Dec. 22, Expion360 announced that the Company has been selected as the exclusive supplier of high-energy lithium ion batteries for an overland trailer to be branded and sold by a top U.S. sports utility vehicle manufacturer. Inspired by military ruggedized surveillance trailers and developed by leaders in advanced vehicle engineering, the award-winning overland trailer sets a new benchmark for off-road performance, comfort and clean power capability. Expion360 state-of-the-art Li-ion batteries have been integrated as a key element of the trailer’s onboard solar-powered storage system. Power systems equipped with Expion360 lithium batteries will be included as standard equipment on the top models. Expion360 plans to begin shipping lithium batteries to the trailer manufacturer in the first quarter of 2023. Expion360 looks forward to a long and prosperous relationship with this manufacturer. The overland trailer is expected to be available for purchase through more than 5,000 SUV dealers across North America starting early next year.

Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward.

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates and let’s find ways to crush it again this year!

Investing & Inspiration

“Be faithful in small things because it is in them that your strength lies.” – Mother Teresa
“The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
“By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius
“No man was ever wise by chance.” – Lucius Annaeus Seneca
“Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
“It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare
“It does not matter how slowly you go as long as you do not stop.” – Confucius
“I want to put a ding in the universe.” – Steve Jobs
“Research is creating new knowledge.” – Neil Armstrong
“The reward for work well done is the opportunity to do more.” – Jonas Salk
“Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
“There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey
“Success seems to be largely a matter of hanging on after others have let go.” – William Feather
“The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger
“More business is lost every year through neglect than through any other cause.” – Rose Kennedy
“Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
“A person who won’t read has no advantage over one who can’t read.” – Mark Twain
“The best way out is always through.” – Robert Frost
“Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi
“Without labor nothing prospers.” – Sophocles
“Intellectuals solve problems, geniuses prevent them.” – Albert Einstein
“This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt
“The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller
“He who is brave is free.” – Lucius Annaeus Seneca
“When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk
“I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin
“Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll
“He who knows that enough is enough will always have enough.” – Lao Tzu
“Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall
“In order to carry a positive action we must develop here a positive vision.” – Dalai Lama
“A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
“Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
“If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
“A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
“You must do the things you think you cannot do.”- Eleanor Roosevelt
“Success is dependent on effort.” – Sophocles
“Nobody who ever gave his best regretted it.” – George Halas
“Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
“And when I breathed, my breath was lightning.” – Black Elk
“Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
“You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
“If you want a guarantee, buy a toaster.” – Clint Eastwood
“We are an impossibility in an impossible universe.” – Ray Bradbury
“If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
“I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
“Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
“It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
“Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
Surprise is the greatest gift which life can grant us.” – Boris Pasternak
“Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran
“Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
“All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
“There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” – Colin Powell
“There is more to life than increasing its speed.” – Mahatma Gandhi
“Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
“Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
“Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
“In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
“Life is too short for long-term grudges.” – Elon Musk
“There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
“Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
“The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
“Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
“Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
“But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
“Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
“Let there be work, bread, water and salt for all.” – Nelson Mandela
“The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
“A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
“I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
“It is the fight alone that pleases us, not the victory.” – Blaise Pascal
“If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
“Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
“Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
“Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
“You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
“Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
“Delete the negative; accentuate the positive!” – Donna Karan
“It’s crazy how fast time flies and how things progress.” – Nathan Chen
“The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
“Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
“Everything has beauty, but not everyone sees it.” – Confucius
“A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
“Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
“A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
“The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
“Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
“I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
“Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
“But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
“Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
“Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
“No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
“Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
“Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
“Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
“If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
“Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
“The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
“There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
“Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
“There is little that can withstand a man who can conquer himself.” – Louis XIV
“In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
“A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
“The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
“Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese
“Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
“Never do anything against conscience even if the state demands it.”– Albert Einstein
“Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
“The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
“In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
“A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
“The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
“Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
“Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
“Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
“No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch
“Start where you are. Use what you have. Do what you can.”– Arthur Ashe
“The secret of getting ahead is getting started.” – Mark Twain
“The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe